Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort

Abstract : Drug survival reflects treatment effectiveness and safety in real life. There is limited data on the variation of drug survival with the availability of systemic treatments with additional biological disease-modifying antirheumatic drugs (bDMARDs) or synthetic disease-modifying antirheumatic drugs (sDMARDs). The aim of this study was to determine whether the increasing number of available systemic treatments for psoriasis affects drug survival over time. Patients were selected from the PsoBioTeq cohort, a French prospective observational cohort enrolling patients with moderate to severe psoriasis. All patients initiating a first bDMARD or sDMARD were included. The primary outcome was comparison of drug survival over time. A multivariate Cox proportional hazard ratio model was computed. A total of 1,866 patients were included; 739 females (39%), median age 47 years. In the multivariate Cox model, no association was found between the calendar year of initiation and drug survival (hazard ratio) over-lapping from 0.80 (0.42–1.52) to 1.17 (0.64–2.17), p = 0.633). In conclusion, drug survival in psoriasis is not affected by the year of initiation.
Liste complète des métadonnées

https://hal.archives-ouvertes.fr/hal-03660920
Contributeur : Laurent Jonchère Connectez-vous pour contacter le contributeur
Soumis le : mardi 31 mai 2022 - 16:34:31
Dernière modification le : vendredi 5 août 2022 - 11:56:06

Fichier

Bettuzzi_document.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Licence


Distributed under a Creative Commons Paternité - Pas d'utilisation commerciale 4.0 International License

Identifiants

Citation

T. Bettuzzi, H. Bachelez, M. Beylot-Barry, H. Arlégui, C. Paul, et al.. Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort. Acta Dermato-Venereologica, Society for Publication of Acta Dermato-Venereologica, 2022, 102, pp.adv00665. ⟨10.2340/actadv.v101.566⟩. ⟨hal-03660920⟩

Partager

Métriques

Consultations de la notice

52

Téléchargements de fichiers

1